CDC’s Traveler Surveillance Program Surpasses One Million Participants, Bolstering US Biosecurity
Table of Contents
The Centers for Disease Control and Prevention’s (CDC) Traveler-Based Genomic Surveillance (TGS) program has reached a landmark achievement, enrolling over one million voluntary participants and significantly enhancing the nation’s capacity to identify and respond to emerging public health threats.
The TGS program, a key component of the United States’ disease surveillance infrastructure, utilizes voluntary and anonymous sample collection from international travelers arriving at select U.S.airports.This proactive approach provides crucial early warnings about new pathogens and variants before they can widely circulate within the country.
Strengthening US Public Health Capabilities
“The United States is the world’s leading authority in public health,” stated a senior official. “The broad participation of travelers enhances our ability to safeguard the nation using tools that are developed, operated, and governed here at home without reliance on unaccountable global bureaucracies.”
Launched in 2021, the TGS program operates through strategic public-private partnerships with organizations like Ginkgo Biosecurity and XWell, alongside collaboration with key U.S. airports. These partnerships are instrumental in generating rapid biosurveillance data, notably valuable when testing and sequencing capabilities are limited in other parts of the world.
Early Detection of Emerging Threats
The program’s effectiveness is already demonstrable. As an example, TGS reported the first two detections of influenza H3N2 subclade K to public repositories a full seven days before the next publicly reported sequence. This early detection underscores the value of a robust, U.S.-based surveillance system.
Beyond nasal samples collected from travelers, the CDC has also analyzed over 2,600 airplane wastewater samples as part of its broader biosurveillance efforts, providing another layer of data for identifying potential outbreaks. The program specifically focuses on monitoring for communicable diseases and the early detection of emerging variants of seasonal respiratory viruses and other pathogens of public health concern.
Commitment to National Biosecurity
The success of TGS reflects a broader commitment to strengthening domestic public health capabilities and ensuring a rapid response to infectious disease threats. According to a statement, the United States will remain a global leader in public health by prioritizing health innovation and enhancing national biosecurity.
Additional information about current TGS data is available here.
Expanded News Report with Answers to Why, Who, What, and How:
Why: The CDC launched the Traveler-Based Genomic Surveillance (TGS) program to proactively identify and respond to emerging public health threats, specifically new pathogens and variants of existing diseases, before they become widespread within the United States. The program aims to strengthen national biosecurity and reduce reliance on international surveillance systems.
Who: The CDC is the lead agency, but the program relies on a network of partners. Key players include: Ginkgo Biosecurity, XWell (private sector partners providing testing and sequencing capabilities), U.S. airports (facilitating sample collection), and over one million voluntary traveler participants. A senior official within the CDC publicly stated the program’s importance.
What: The TGS program is a genomic surveillance system that collects voluntary and anonymous nasal samples from international travelers arriving at select U
Related reading
